Partial Salvage Cryoablation Of The Prostate For Recurrent Prostate Cancer After Radiotherapy Failure
August 4th, 2008 by allsoch
UroToday.com - In the online edition of Urology, Drs. Michael Eisenberg and Katsuto Shinohara reported on their experience using partial (unilobar) cryotherapy for patients with a local recurrence of prostate cancer (CaP) following radiotherapy (XRT).
Between 2004 and 2007, 19 patients had failed XRT by either the ASTRO or Phoenix criteria. All had 16-core prostate biopsies performed to document recurrence, and metastatic evaluations were negative. Gleason grading post-XRT was not done.
Posted in Uncategorized | No Comments »
A prominent US cancer institute has posted a notice on its website urging cell phone users to take precautions when using cell phones because advice from an international panel of experts says cell phones have not been around long enough for scientists to be sure about their safety.
Merck KGaA announced today that it has been granted approval by the European Commission for Erbitux® (cetuximab), to update its license for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type mCRC (metastatic colorectal cancer) in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
The St. Louis Post-Dispatch on Sunday examined the “life-and-death” decisions pregnant women with cancer must make and the treatment options available to them. According to the Post-Dispatch, as many as one in every 1,000 pregnant women in the U.S. is diagnosed with cancer. As more women delay childbirth into their 30s and 40s, some doctors believe the rate will increase because such women are at an increased risk of developing cancer.
Researchers at Case Western Reserve University have developed a technique that has the potential to deliver cancer-fighting drugs to diseased areas within hours, as opposed to the two days it currently takes for existing delivery systems.
Although a growing body of research supports a link between effective communication and patient, family and physician satisfaction, doctors, including oncologists and other specialists who frequently care for terminal patients, do not routinely receive training in end-of-life conversations during medical school, residency training, or after they start to practice medicine.
A team of Scottish researchers have shown that cancer patients offered a depression care intervention - delivered by specially trained oncology nurses with no previous psychiatric experience - showed improvements in symptoms of depression compared to patients offered usual care. The beneficial effects of the “Depression Care for People with Cancer” package (DCPC) were found to be sustained at 12 months follow-up, to the surprise of the investigators.
Doctors at Melbourne Internal Medical Associates (MIMA) Cancer Center have become the first in Florida to treat cancer using RapidArc™ radiotherapy technology from Varian Medical Systems (NYSE: VAR). They are also the first in the world to use this technology to deliver stereotactic body radiotherapy (SBRT) in the treatment of soft tissue carcinoma.
Veritas Medical Solutions, LLC has been formed to provide worldwide customers with a single source solution for cancer treatment rooms. Focused on providing innovative modular designs, products and services, the company provides all the pieces necessary for a rapid, turnkey therapy room installation.
Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics’ proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program. CUMC is now finalizing the commercial aspects of this test and will announce its clinical availability to patients nationwide once details are finalized later this year.